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Background. Interest to assess short-term beneﬁts or risks of sex-steroid hormone use (OC or HRT) exists for years. However,
no validated scale is available to evaluate the broad array of described eﬀects of short-term hormone use. Methods.Ar a ws c a l e
consisting of 43 speciﬁc items and 47 general data was developed. Surveys in Italy, Germany and Austria were performed and
data analyzed by factorial analyses. The resulting new scale with 15 items underwent reliability and validity investigations. Results.
The new scale consists of 15 items in 5 domains. Internal consistency reliability coeﬃcients were satisfactory as were test-retest
reliability coeﬃcients. Content and concurrent validity were promising. Conclusion. Psychometric properties of the new scale
suggest good characteristics to measure short-term eﬀects of sex-steroid hormones in women. The scale seems to be appropriate,
feasible, interpretable, reliable, and valid for their application as PRO scale.
Copyright © 2009 Lothar A. J. Heinemann. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1.Introduction
For years, there has been an interest to evaluate short-term
beneﬁts or risks of sex-steroid hormone use in women, and
many studies using nonvalidated scales were published. No
validated scale was available that met the methodological
guidelines for patient-reported outcome scales [1], that
is, meeting the “state-of-the-art” psychometric require-
ments relevant for health-related quality-of-life (HRQoL)
scales.
A variety of shorter or longer simple symptom lists
were developed and applied in clinical studies, that is,
only subjectively comparing the situation before and after
hormone treatment in women. Such lists covered a broad
array of clinically discussed short-term eﬀect of hormone
use such as skin and hair eﬀects, eﬀects on breast, on
menstrual cycle/bleeding pattern, on aspects of sexual life,
on psychological problems/symptoms, and on vegetative
complaints associated with sex hormone use which will be
discussed later.
The aim of this paper is to clarify if a validated meas-
urement scale for short-term use of sex hormones can be
developed and if yes, how the diagnostic characteristics such
as reliability and validity of measurement might be.
2.MaterialandMethods
Pertinent literature was scrutinized to get suggestions about
potential self-perceived short-term beneﬁts or adverse eﬀects
associated with the use of sex-steroid hormones such as
sexual dysfunction particular during menopausal transition,
problems of menstrual bleeding in general, hair and skin
problems including breast tension/pain, and increasing body
weightandalsopositiveeﬀectsofhormonesonpremenstrual
syndrome complaints were reported. Relief of menorrhagia,
shortening of duration of bleeding [2], or treatment of
dysfunctional uterine bleeding [3] including improvement
of iron deﬁciency are commonly accepted beneﬁts. The
eﬀects of controlling acne in combination drugs with certain
progestagens [4, 5], or improvement of seborrhea [6, 7],
weredocumented.Moredebateswerefoundabouthormonal
eﬀect on bleeding cycle-related disturbances [8–10].
In addition, standardized HRQoL and other scales
formerly used in clinical studies related to sex hormone use
were reviewed to complete the array of interesting items
potentially related with hormone use. This included the
MenopauseRating Scale[11], theQualityof SexualFunction
Scale,[12]theFemaleSexualFunctionIndex(FSFI)[13],the
DerogatesInterviewforSexualFunctioning (DISF)[14],and2 Obstetrics and Gynecology International
the Female Sexual Distress Scale (FSDS) [15]. This included
also experience gathered in studies with the Aging Males
Symptoms Scale (AMS) [16].
Own observational (prevalence) surveys in women
(patients) with/without hormone use identiﬁed many diﬀer-
ences in complaints between treated and untreated women
and thereby candidates for items of a new scale (unpublished
report) as well as a large, observational study in 9 countries
in 4 continents [17] contributed also to the identiﬁcation
of possible problems or concerns of women (unpublished
report).
The preparatory work resulted in a conceptual frame-
work with ﬁve arbitrarily deﬁned groups of items that could
be relevant for a new validated scale (Table 1): psychological
complaints (n = 8), somato-vegetative (n = 5), menstrual
disorders (n = 8), sexual items (n = 13), and complaints
related to hormone-sensitive organs (n = 7). The resulting
rawscaleconsistedof43speciﬁcitems(suspectedshort-term
eﬀects of sex steroid hormones), and of 47 general informa-
tion (medical and reproductive history, demographic data)
needed for the interpretation and item reduction.
The format of the new scale was planned as paper-based
scale. Response categories at a Likert scale from 1 (= no,
never) to 5 (= yes, severe) describe the personally perceived
severity (or intensity) of complaints (items). All speciﬁc
items were phrased in a negative direction (complaints)
following own experiences with the development of other
HRQoL scales [11, 12, 16]. If an item is not relevant, for
example, the question of problems concerning menstrual
bleeding in case of absence of menstrual cycle, “0” (no, not
applicable) can be checked.
Thus, the raw scale consisted of an introduction, two
examples as how to answer the questionnaire correctly, and
the 90 items to be answered. The English version of the
raw scale underwent a linguistic and cultural adaptation into
Italian and German languages.
The statistical analyses are based on factorial analysis
(main component analysis), Cronbach’s alpha coeﬃcient for
internal consistency reliability, and test-retest-reliability. The
statistical package SPSS 10 was used.
3. Results andDiscussion
3.1. Development. The initial normative survey (Italy)
involved 228 women aged 15–65 years. This was a sample
of the normal female population, that is, not only women
using hormones. This approach was chosen to get standard
or norm values of the female population.
In a few steps of factorial analysis the number of items
could be reduced and the domains of the ﬁnal scale with 15
items determined.
Five dimensions (domains) were found, as similarly
predicted in the conceptual framework (Table 2): sexual
problems (SEX), menstrual problems (MENS), hormonal
eﬀects (HORM), psychological problems (PSYCH), and
abdominal complaints (ABDOM). Table 2 summarizes the
ﬁndings. For easy recognition and interpretation, only factor
loadings over 0.5 were displayed.
In an independent population survey in Germany (n =
108), the same 5 domains were observed with factor loadings
very similar if not identical with the Italian sample (data not
shown here).
This supports the notion that the new scale and its
domains have a quite good face or content validity conﬁrmed
in two independent studies.
3.2. Reliability. The internal consistency reliability—
measured with Cronbach’s Alpha—was good (r = 0.74) for
the total scale and acceptable for the ﬁve domains with one
exception: 0.73 on PSYCH, 0.73 HORM, 0.78 for MENS,
0.81 SEX, but unsatisfactory for ABDOM(= 0.53). The latter
needs further research. The results were conﬁrmed in the
German validation study.
Additional information provided the item-domain cor-
relation that showed strong associations of all items with
the respective domains, however, with one exception: the
items“cyclicbleedingfromgutsorbladder”withthedomain
“abdominal complaints” with a coeﬃcient of 0.39.
Another aspect of reliability, test-retest reliability, was
tested in a validation survey in Germany (n = 108): a very
good reliability was observed for the total score (r = 0.92),
and for the ﬁve domain scores: 0.83 for PSYCH, 0.85 for
HORM, 0.93 for MENS, 0.72 for SEX, but unsatisfactory for
ABDOM(=0.62).Thecorrelationcoeﬃcientswerealsogood
across almost all items of the scale. The test-retest reliability
studyconﬁrmedwhathasbeenshowninthetwostudieswith
analyses of Cronbach’s alpha.
3.3. Validity. The ﬁrst step of validation is the comparability
oftheinternalstructure (dimensions)ofanewscalethrough-
out independent factor analyses and compatibility with the
conceptual framework. This is indicative with a good face-
or content-validity.
Since the SHE scale was designed also as health-related
QoL scale with speciﬁc focus on short-term hormonal
eﬀects, we were particularly interested in evidence that the
SHE scale really measures quality of life: the SHE total score
signiﬁcantly correlated with the generic QoL scale SF-12
(total, physical, and mental health score) [18] in the German
survey and similarly in an Austrian sample. The correlation
coeﬃcients were signiﬁcant but not high, that is, ranging
between r = 0.3a n dr = 0.8).
Other signiﬁcant but low correlations were observed
between domains of the SHE-scale and the domain anxiety
of the HADS [19] as well as with the domain psychosomatic
QoL of the QSF in the German survey (ranging between
r = 0.3a n dr = 0.6).
The psychological domain of the SHE scale showed—as
the total score—signiﬁcant association with mental health
andtotalscoreofSF-12,anxiety(HADS),andpsychosomatic
QoL (QSF) (range: r = 0.3–r = 0.6). The hormone-
related domain showed correlations with SF-12 as well as
QSF (range: r = 0.4–r = 0.5). The highest correlation
of the abdominal domain of SHE was observed with SF-
12 (total and physical health domain) (r = 0.6). TheObstetrics and Gynecology International 3
Table 1: Conceptual framework and grouping of the complaints or symptoms possibly relevant for measuring short-term eﬀects of
hormones (raw scale). These “multicausal symptoms” were arbitrarily allocated to one of the ﬁve groups, that is, the groups are not mutually
exclusive.
Groups where symptoms or complaints might be related to
Psychological
complaints
Somato-vegetative
complaints
Menstrual, abdominal
disturbances
Sexually related
symptoms
Problems with
hormone-sensitive
Organs
Total
number of
symptoms
10 5 8 13 7
Listing of
items of
the raw
scale
Reduced general
well-being
Episodes of sudden
sweating
Abdominal boating or
swelling
Reduced sexual
desire/libido
Breast tenderness or
pain
Depressive mood Increased appetite,
food craving Abdominal pain
Reduced enjoyment
of books or movies
associated with sex
Temporary weight gain
Sensation of loneliness Nausea, dizziness Cramps of guts or
bladder
Less sexual fantasies/
thoughts Swelling of extremities
Easily anxious Joint and muscular
discomfort
Cyclic bleeding from
guts or bladder
Sexual life less
enjoyable/ satisfying Greasy skin or acne
Feeling worried Heart discomfort Irregular menstrual
bleeding
Less satisfaction/
enjoyment with
sexual act
Hair disorders or
problems
Restlessness or
irritability
Strong menstrual
bleeding
Reduced vaginal
lubrication during sex
Unexpected growth of
body or facial hair
Physical exhaustion Painful menstrual
period
Reduced sexual
arousal Suﬀering from cellulite
Impaired capacity to
concentrate
Signiﬁcant premenstrual
complaints that improve
when menstrual ﬂow
began
Less sexual activity
Impaired memory Lower frequency
of orgasm
Sleep problems Less satisfaction
with orgasm
Pain during or
after sex
Bladder problems
Dryness or burning
vagina
menstrual domain showed only a weak correlation with SF-
12. The sexual domain score was correlated with anxiety
(HADS) and with psychological QoL (QSF) (range r = 0.3
to r = 0.4).
Altogether,theSHEscalewithitstotalanddomainscores
seem to be correlated with other scales intending to measure
a similar content.
3.4. Ability to Detect Changes. Since the SHE scale was
not yet applied in treatment-related observational or the
randomized clinical studies, there are no data to describe
responsiveness or MID.
The next step will be an analysis of the sensitivity of
the SHE scale to detect the eﬀects of hormonal treatment.
Therefore, the SHE scale should be included in relevant
observationaltreatmentstudiesorrandomizedclinicaltrials,
that is, including also independent outcome variables for
validation in the study.
The complete design/wording of the SHE scale (in Ger-
man, English, Italian languages), the evaluation procedure,4 Obstetrics and Gynecology International
Table 2: Internal structure of the “Short-term Hormonal Eﬀects (SHEs)” scale (factorial analysis; Italian normative survey; n = 228). The
analysis determined ﬁve domains (explaining 66.1% of the total variance). The numbers in the table are factor loadings. Only loadings over
0.5 are shown.
Factors/Domains
Items (1) SEX (2) MENS (3) HORM (4) PSYCH (5) Abdom
(1) Depressive mood 0.76
(2) Feeling worried 0.83
(3) Restlessness or irritability 0.77
(4) Increased appetite, food
cravings
0.67
(5) Temporary weight gain 0.80
(6) Swelling of extremities 0.81
(7) Painful menstrual period 0.85
(8) Signiﬁcant premenstrual
complaints that improve when the
menstrual ﬂow began
0.80
(9) Strong menstrual bleeding 0.81
(10) Less sexual fantasies/thoughts 0.83
(11) Less satisfaction/enjoyment
with sexual act
0.83
( 1 2 ) R e d u c e ds e x u a la r o u s a l 0.82
(13) Abdominal pain 0.61
(14) Cyclic bleedings from guts or
bladder
0.79
(15) Cramps of guts or bladder 0.50
and reference (norm) values from the Italian, German,
and Austrian population sample is openly accessible in
the oﬃcial website for the SHE scale (http://www.short-
term-hormone-eﬀects-scale.info). The scale can be used free
of charge.
4. Conclusions
The newly developed SHE scale could close a gap for clinical
research to measure short-term eﬀects of sex-steroid hor-
mones in women that were widely applied to demonstrate
diﬀerences between relevant drugs. In the past, however,
simple symptom lists based on the retrospective perception
of an “improvement of conditions/complaints after therapy”
or other not validated instruments were used as argument
that speciﬁc formulations of sex-steroid hormones are
better than others. Such not validated questionnaires lead
to unreliable “beneﬁts.” Although until now no validated
scale was available meeting the FDA requirements for PRO
scales, there is great interest of the industry to demonstrate
“additional short-term beneﬁts” of a newly developed drug
containing sex steroid hormones in women because so many
drugs are already on the market.
The assessment of the properties of the SHE scale is
indicative of good characteristics to measure short-term
eﬀectsofsex-steroidhormonesinwomen.Thescaleseemsto
be appropriate, feasible, interpretable, reliable, and valid for
their application as PRO scale. Data to assess responsiveness
and sensitivity of the scale as outcome measure of hormone
treatment are still lacking.
This validated scale can be recommended for practical
use in comparative studies in order to avoid misjudgment
concerning “beneﬁts” provided by nonvalidated symptom
lists with subjectively perceived “improvement” of drug A
over drug B. As self-administered scale, the self-completion
of the 15-item-scale takes less than 7 minutes on average.
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